DK2683245T4 - Fremgangsmåder og sammensætninger til behandling af depression ved anvendelse af cyclobenzaprin - Google Patents

Fremgangsmåder og sammensætninger til behandling af depression ved anvendelse af cyclobenzaprin Download PDF

Info

Publication number
DK2683245T4
DK2683245T4 DK12755254.5T DK12755254T DK2683245T4 DK 2683245 T4 DK2683245 T4 DK 2683245T4 DK 12755254 T DK12755254 T DK 12755254T DK 2683245 T4 DK2683245 T4 DK 2683245T4
Authority
DK
Denmark
Prior art keywords
cyclobenzaprine
compositions
methods
treating depression
depression
Prior art date
Application number
DK12755254.5T
Other languages
Danish (da)
English (en)
Other versions
DK2683245T3 (da
Inventor
Seth Lederman
Original Assignee
Tonix Pharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46796107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2683245(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tonix Pharma Holdings Ltd filed Critical Tonix Pharma Holdings Ltd
Publication of DK2683245T3 publication Critical patent/DK2683245T3/da
Application granted granted Critical
Publication of DK2683245T4 publication Critical patent/DK2683245T4/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK12755254.5T 2011-03-07 2012-03-06 Fremgangsmåder og sammensætninger til behandling af depression ved anvendelse af cyclobenzaprin DK2683245T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161449838P 2011-03-07 2011-03-07
PCT/US2012/027926 WO2012122193A1 (en) 2011-03-07 2012-03-06 Methods and compositions for treating depression using cyclobenzaprine

Publications (2)

Publication Number Publication Date
DK2683245T3 DK2683245T3 (da) 2020-02-24
DK2683245T4 true DK2683245T4 (da) 2023-01-09

Family

ID=46796107

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12755254.5T DK2683245T4 (da) 2011-03-07 2012-03-06 Fremgangsmåder og sammensætninger til behandling af depression ved anvendelse af cyclobenzaprin

Country Status (18)

Country Link
US (1) US11998516B2 (enExample)
EP (2) EP2683245B2 (enExample)
JP (2) JP2014507475A (enExample)
AU (4) AU2012225548B2 (enExample)
CA (1) CA2829200C (enExample)
CY (1) CY1122998T1 (enExample)
DK (1) DK2683245T4 (enExample)
ES (1) ES2773834T5 (enExample)
FI (1) FI2683245T4 (enExample)
HR (1) HRP20200142T4 (enExample)
HU (1) HUE048596T2 (enExample)
LT (1) LT2683245T (enExample)
PL (1) PL2683245T5 (enExample)
PT (1) PT2683245T (enExample)
RS (1) RS60240B2 (enExample)
SI (1) SI2683245T2 (enExample)
SM (1) SMT202000083T1 (enExample)
WO (1) WO2012122193A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037281T2 (hu) * 2009-11-20 2018-08-28 Tonix Pharma Holdings Ltd Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
SMT202000045T1 (it) 2013-03-15 2020-05-08 Tonix Pharma Holdings Ltd Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo
WO2015150948A1 (en) * 2014-03-29 2015-10-08 Wockhardt Limited Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof
CA2961822A1 (en) * 2014-09-18 2016-03-24 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride
CN106890129A (zh) * 2015-12-18 2017-06-27 健乔信元医药生技股份有限公司 环苄普林之延释剂型
CA3083341C (en) * 2017-12-11 2024-05-28 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3882246A (en) 1971-05-21 1975-05-06 Merck & Co Inc Treatment of skeletal muscle disorders with cyclobenzaprine
US4968507A (en) 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
FR2635461B1 (fr) 1988-08-18 1992-01-17 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
NZ262679A (en) 1993-02-22 1997-08-22 Vivorx Pharmaceuticals Inc Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5354566A (en) 1993-06-02 1994-10-11 Kraft General Foods, Inc. Preparation of yeast-leavened dough crusts
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
PT1077683E (pt) 1998-05-14 2003-04-30 Alza Corp Terapia anti-depressiva
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
HK1047692A1 (zh) * 1999-08-13 2003-03-07 Vela Pharmaceuticals Inc 治疗全身性焦虑障碍的环苯扎林及其组合物
ATE299369T1 (de) 1999-08-13 2005-07-15 Vela Pharmaceuticals Inc Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
AU2001261744A1 (en) 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
CA2463987C (en) 2001-11-05 2011-03-08 Seth Lederman Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
JP4288263B2 (ja) 2002-10-25 2009-07-01 コレジウム ファーマシューティカル, インク. p−ヒドロキシ−ミルナシプランの立体異性体およびその使用方法
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
US20050059656A1 (en) 2003-04-07 2005-03-17 Cornell Research Foundation, Inc. Compositions and methods for protecting against mitochondria component-mediated pathology
EP1644019B2 (en) 2003-05-29 2018-02-21 Shire LLC Abuse resistant amphetamine compounds
CA2543710A1 (en) 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
US20050143350A1 (en) 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005055983A2 (en) 2003-12-09 2005-06-23 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
KR20070030178A (ko) 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
TW200531680A (en) 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7532935B2 (en) 2005-07-29 2009-05-12 Cyberonics, Inc. Selective neurostimulation for treating mood disorders
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20090069267A1 (en) 2006-01-17 2009-03-12 Abrams Daniel J Central administration of stable formulations of therapeutic agents for cns conditions
US20080146672A1 (en) 2006-12-08 2008-06-19 Denton Marcia Marye Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
EP2514417A3 (en) 2007-05-07 2013-01-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
CA2690737A1 (en) 2007-06-22 2008-12-31 Merck Sharp & Dohme Corp. 6.5-pyrrolopiperidine tachykinin receptor antagonists
CA2707858A1 (en) 2007-07-23 2009-01-29 Synosia Therapeutics, Inc. Treatment of post-traumatic stress disorder
US20090060983A1 (en) 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
HUE043897T2 (hu) 2007-09-25 2019-09-30 Solubest Ltd Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra
EP2203158A4 (en) 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
US20090148532A1 (en) 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
AU2009212373B2 (en) 2008-02-08 2013-10-03 Foresee Pharmaceuticals Co., Ltd. Non-polymeric compositions for controlled drug delivery
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
JP5380909B2 (ja) 2008-05-30 2014-01-08 株式会社ブリヂストン 金型及び樹脂発泡成形品の成形方法
US20100266682A1 (en) 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
US20100247586A1 (en) 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
US8343533B2 (en) 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
HUE037281T2 (hu) 2009-11-20 2018-08-28 Tonix Pharma Holdings Ltd Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
EP2611440B1 (en) 2010-09-01 2017-02-01 Tonix Pharmaceuticals, Inc. Treatment for cocaine addiction
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
ITMI20110558A1 (it) 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
LT2861223T (lt) 2012-06-15 2022-12-12 Tonix Pharma Holdings Limited Kompozicijos ir būdai, skirti absorbavimui per gleivinę
ES2823237T3 (es) 2012-11-05 2021-05-06 Univ Emory Derivados de 7,8-dihidroxiflavona y de flavona 7,8-sustituida, composiciones y métodos relacionados con los mismos
SMT202000045T1 (it) 2013-03-15 2020-05-08 Tonix Pharma Holdings Ltd Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo
MX2017004772A (es) 2014-07-18 2017-10-12 Medipath Inc Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
CA2961822A1 (en) 2014-09-18 2016-03-24 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride
CA3083341C (en) 2017-12-11 2024-05-28 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
WO2023250036A1 (en) 2022-06-21 2023-12-28 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc)

Also Published As

Publication number Publication date
ES2773834T5 (es) 2023-03-16
AU2018204633A1 (en) 2018-07-12
AU2012225548A1 (en) 2013-09-19
NZ614725A (en) 2016-07-29
JP2016053095A (ja) 2016-04-14
EP3682885A1 (en) 2020-07-22
EP2683245A4 (en) 2014-08-27
RS60240B1 (sr) 2020-06-30
CA2829200C (en) 2022-05-03
WO2012122193A1 (en) 2012-09-13
AU2016222412B2 (en) 2018-03-29
HRP20200142T1 (hr) 2020-06-26
FI2683245T4 (fi) 2023-01-13
EP2683245B1 (en) 2019-12-25
LT2683245T (lt) 2020-03-25
AU2020203874A1 (en) 2020-07-02
US11998516B2 (en) 2024-06-04
ES2773834T3 (es) 2020-07-15
SI2683245T2 (sl) 2023-04-28
CA2829200A1 (en) 2012-09-13
EP2683245A1 (en) 2014-01-15
CY1122998T1 (el) 2021-10-29
AU2018204633C1 (en) 2020-09-10
US20120232159A1 (en) 2012-09-13
RS60240B2 (sr) 2023-05-31
EP2683245B2 (en) 2022-12-07
AU2018204633B2 (en) 2020-03-12
PL2683245T5 (pl) 2023-03-20
SMT202000083T1 (it) 2020-05-08
HUE048596T2 (hu) 2020-08-28
AU2016222412A1 (en) 2016-09-22
HRP20200142T4 (hr) 2023-02-17
AU2020203874B2 (en) 2021-09-09
SI2683245T1 (sl) 2020-07-31
NZ714294A (en) 2017-06-30
PL2683245T3 (pl) 2020-10-05
JP2014507475A (ja) 2014-03-27
PT2683245T (pt) 2020-02-21
DK2683245T3 (da) 2020-02-24
AU2012225548B2 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
DK2890780T3 (da) Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
DK4011364T3 (da) Fremgangsmåder og sammensætninger til behandling af ADD (Attention Deficit Disorder)
DK2709613T4 (da) Fremgangsmåder til behandling af hcv
DK3875104T3 (da) Sammensætninger til behandling af ineffektiv erytropoiese
DK2900061T3 (da) Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
DK2914741T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til forbedring af PCR-specificitet
DK2776567T3 (da) Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.
DK2812452T3 (da) Fremgangsmåder og sammensætninger til screening og behandling af udviklingsforstyrrelser
DK3141542T3 (da) Substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsiltning
DK2768321T3 (da) Fremgangsmåder og sammensætninger til induktion af mæthed
BR112013019732A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
DK2699553T3 (da) Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3586861T3 (da) Lipidnanopartikelsammensætninger og fremgangsmåder til mrna-indgivelse
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK2884999T3 (da) Fremgangsmåde og sammensætninger til cellulær immunterapi
DK2583586T4 (da) Indretning til registrering af kollisioner og tilsvarende fremgangsmåde
DK2830654T3 (da) Metoder og sammensætninger til behandling af inflammation
DK2766483T3 (da) Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser
DK2552484T3 (da) Fremgangsmåder og sammensætninger til reducering af parathyroidniveauer
DK2683245T4 (da) Fremgangsmåder og sammensætninger til behandling af depression ved anvendelse af cyclobenzaprin
DK2877856T3 (da) Fremgangsmåde til forbedring af implantationssucces ved assisteret befrugtning
DK2793895T3 (da) Fremgangsmåder og sammensætninger til reducering af kropsfedt og adipocytter
DK2917231T3 (da) Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme
DK2680829T3 (da) Sammensætninger og metoder til ikke-kirurgisk behandling af ptosis
DK2683371T3 (da) Forbindelser og fremgangsmåder til forbedring af forringet endogen fibrinolyse ved anvendelse af histondeacetylasehæmmere